[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.3.44. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 85
Citations 0
Invited Commentary
January 25, 2017

Intraductal Papillary Mucinous Neoplasm Around the WorldAre We Seeing Things the Same Way?

Author Affiliations
  • 1Unit of General and Pancreatic Surgery, Department of Surgery and Oncology, The Pancreas Institute, University of Verona Hospital Trust, Verona, Italy
  • 2Department of Surgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia
JAMA Surg. Published online January 25, 2017. doi:10.1001/jamasurg.2016.5055

In the current era of personalized surgery, great efforts are being made to refine surgical indications for intraductal papillary mucinous neoplasm (IPMN). The controversial article by Hirono et al1 from Japan in this issue of JAMA Surgery addresses this topic by retrospectively reviewing 286 patients who underwent resection for IPMN, with the aim of identifying factors associated with malignancy specific to each IPMN morphological type. Among others, larger mural nodule size for all types and high carcinoembryonic antigen levels in the pancreatic juice for main duct and mixed IPMNs were found to be associated with invasive behavior. Hirono et al1 found that these factors correlated with malignancy more accurately than current, established guidelines.2,3

First Page Preview View Large
First page PDF preview
First page PDF preview
×